Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free HSCS Stock Alerts

HeartSciences (HSCS) Competitors

HeartSciences logo
$2.03 -0.01 (-0.49%)
Closing price 04:00 PM Eastern
Extended Trading
$2.06 +0.03 (+1.63%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

HSCS vs. MLSS, FEMY, ICCM, POAI, and RVP

Should you be buying HeartSciences stock or one of its competitors? The main competitors of HeartSciences include Milestone Scientific (MLSS), Femasys (FEMY), IceCure Medical (ICCM), Predictive Oncology (POAI), and Retractable Technologies (RVP). These companies are all part of the "medical equipment" industry.

How does HeartSciences compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Milestone Scientific has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

In the previous week, HeartSciences had 2 more articles in the media than Milestone Scientific. MarketBeat recorded 2 mentions for HeartSciences and 0 mentions for Milestone Scientific. Milestone Scientific's average media sentiment score of 0.00 equaled HeartSciences'average media sentiment score.

Company Overall Sentiment
Milestone Scientific Neutral
HeartSciences Neutral

Milestone Scientific presently has a consensus price target of $1.00, suggesting a potential upside of 151.26%. HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 294.09%. Given HeartSciences' higher possible upside, analysts plainly believe HeartSciences is more favorable than Milestone Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Scientific
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
HeartSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

5.8% of Milestone Scientific shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 12.5% of Milestone Scientific shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

HeartSciences has a net margin of 0.00% compared to Milestone Scientific's net margin of -52.01%. Milestone Scientific's return on equity of -60.26% beat HeartSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone Scientific-52.01% -60.26% -40.23%
HeartSciences N/A -333.50%-140.18%

Milestone Scientific has higher revenue and earnings than HeartSciences. Milestone Scientific is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Scientific$8.97M3.57-$6.93M-$0.06N/A
HeartSciencesN/AN/A-$8.77M-$4.94N/A

Summary

Milestone Scientific beats HeartSciences on 7 of the 13 factors compared between the two stocks.

How does HeartSciences compare to Femasys?

HeartSciences (NASDAQ:HSCS) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

HeartSciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.26, meaning that its stock price is 326% less volatile than the S&P 500.

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 7.6% of Femasys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

HeartSciences has a net margin of 0.00% compared to Femasys' net margin of -812.74%. HeartSciences' return on equity of -333.50% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
HeartSciencesN/A -333.50% -140.18%
Femasys -812.74%-534.94%-116.29%

HeartSciences has higher earnings, but lower revenue than Femasys. Femasys is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HeartSciencesN/AN/A-$8.77M-$4.94N/A
Femasys$2.29M10.54-$18.63M-$0.50N/A

In the previous week, HeartSciences had 1 more articles in the media than Femasys. MarketBeat recorded 2 mentions for HeartSciences and 1 mentions for Femasys. HeartSciences' average media sentiment score of 0.00 equaled Femasys'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HeartSciences
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Femasys
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

HeartSciences currently has a consensus price target of $8.00, suggesting a potential upside of 294.09%. Femasys has a consensus price target of $5.50, suggesting a potential upside of 1,276.72%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than HeartSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HeartSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Femasys
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

Femasys beats HeartSciences on 8 of the 14 factors compared between the two stocks.

How does HeartSciences compare to IceCure Medical?

HeartSciences (NASDAQ:HSCS) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

HeartSciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 4.9% of HeartSciences shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

HeartSciences has a net margin of 0.00% compared to IceCure Medical's net margin of -445.61%. IceCure Medical's return on equity of -221.04% beat HeartSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
HeartSciencesN/A -333.50% -140.18%
IceCure Medical -445.61%-221.04%-118.89%

HeartSciences has higher earnings, but lower revenue than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HeartSciencesN/AN/A-$8.77M-$4.94N/A
IceCure Medical$3.38M6.84-$15.06M-$0.24N/A

In the previous week, HeartSciences had 1 more articles in the media than IceCure Medical. MarketBeat recorded 2 mentions for HeartSciences and 1 mentions for IceCure Medical. HeartSciences' average media sentiment score of 0.00 equaled IceCure Medical'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HeartSciences
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
IceCure Medical
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

HeartSciences currently has a consensus target price of $8.00, suggesting a potential upside of 294.09%. IceCure Medical has a consensus target price of $2.64, suggesting a potential upside of 825.54%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than HeartSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HeartSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
IceCure Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

HeartSciences and IceCure Medical tied by winning 7 of the 14 factors compared between the two stocks.

How does HeartSciences compare to Predictive Oncology?

HeartSciences (NASDAQ:HSCS) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

In the previous week, HeartSciences had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for HeartSciences and 1 mentions for Predictive Oncology. HeartSciences' average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HeartSciences
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Predictive Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

HeartSciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500.

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 4.9% of HeartSciences shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

HeartSciences has higher earnings, but lower revenue than Predictive Oncology. HeartSciences is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HeartSciencesN/AN/A-$8.77M-$4.94N/A
Predictive Oncology$1.66M10.60-$12.66M-$13.50N/A

HeartSciences currently has a consensus target price of $8.00, suggesting a potential upside of 294.09%. Given HeartSciences' stronger consensus rating and higher probable upside, equities analysts plainly believe HeartSciences is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HeartSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

HeartSciences has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. HeartSciences' return on equity of -333.50% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
HeartSciencesN/A -333.50% -140.18%
Predictive Oncology -5,065.23%-732.73%-235.55%

Summary

HeartSciences beats Predictive Oncology on 12 of the 14 factors compared between the two stocks.

How does HeartSciences compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Retractable Technologies has higher revenue and earnings than HeartSciences. Retractable Technologies is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Retractable Technologies$38.27M0.57-$7.01M-$0.42N/A
HeartSciencesN/AN/A-$8.77M-$4.94N/A

Retractable Technologies has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by company insiders. Comparatively, 4.9% of HeartSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

HeartSciences has a net margin of 0.00% compared to Retractable Technologies' net margin of -41.11%. Retractable Technologies' return on equity of -17.15% beat HeartSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Retractable Technologies-41.11% -17.15% -9.33%
HeartSciences N/A -333.50%-140.18%

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 294.09%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Retractable Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Retractable Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
HeartSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, HeartSciences had 1 more articles in the media than Retractable Technologies. MarketBeat recorded 2 mentions for HeartSciences and 1 mentions for Retractable Technologies. Retractable Technologies' average media sentiment score of 0.00 equaled HeartSciences'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Retractable Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
HeartSciences
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

HeartSciences beats Retractable Technologies on 8 of the 14 factors compared between the two stocks.

Get HeartSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for HSCS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HSCS vs. The Competition

Export
MetricHeartSciencesMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$6.50M$1.52B$6.25B$11.77B
Dividend YieldN/AN/A2.74%5.26%
P/E Ratio-0.4161.8329.2527.07
Price / SalesN/A6.24504.1475.42
Price / CashN/A23.1943.3053.90
Price / Book11.284.779.676.69
Net Income-$8.77M-$54.60M$3.55B$332.64M
7 Day Performance1.50%1.14%1.70%2.01%
1 Month Performance-11.74%10.40%5.62%9.19%
1 Year Performance-42.08%8.78%34.42%39.59%

HeartSciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HSCS
HeartSciences
2.1371 of 5 stars		$2.03
-0.5%		$8.00
+294.1%		N/A$6.50MN/AN/A10
MLSS
Milestone Scientific
1.2258 of 5 stars		$0.31
-4.9%		$1.00
+222.6%		N/A$24.94M$8.97MN/A30
FEMY
Femasys
1.8103 of 5 stars		$0.37
0.0%		$5.50
+1,374.9%		N/A$22.52M$2.29MN/A30
ICCM
IceCure Medical
2.16 of 5 stars		$0.27
-1.3%		$2.64
+875.6%		N/A$21.93M$3.38MN/A60
POAI
Predictive Oncology
0.0395 of 5 stars		$5.93
-11.0%		N/AN/A$20.13M$1.66MN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HSCS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel